NASDAQ · PRTC
Healthcare · Biotechnology
$17.42
Up+$0.36 (+2.12%)
Updated Aug 16, 2026, 12:19 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PRTC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PRTC.
PRTC research
Company profile and research snapshot.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Peel Hunt Limited | Buy | — |
| Dec 8, 2025 | Peel Hunt Limited | Buy | — |
| Dec 16, 2024 | Jefferies | Buy | — |
| Dec 7, 2021 | Liberum Capital | Reiteration | — |
| Nov 26, 2021 | Liberum Capital | Reiteration | — |
No generated briefing is available yet.
Benzinga · Feb 19, 2026
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that the
SeekingAlpha · Jan 14, 2026
PureTech Health plc (PRTC) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 7:30 PM ESTCompany ParticipantsRobert Lyne - CEO &...
Yahoo · Dec 8, 2025
PureTech Health (PRTC) said Monday that it completed the end-of-phase 2 meeting with the US Food and
Yahoo · Dec 8, 2025
BOSTON, December 08, 2025--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRTC.
